Yumanity Therapeutics Inc expected to post a loss of 95 cents a share - Earnings Preview
Yumanity Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Brief: Yumanity Therapeutics Reports Full-Year 2021 Financial Results
Brief: Yumanity Terminated Loan Agreement To Support Efforts To Explore Strategic Alternatives
Yumanity falls on restructuring plans, workforce cut
NASDAQ RESUMED AT 09:00 AM
Brief: Yumanity Therapeutics Exploring Strategic Alternatives To Enhance Shareholder Value And Announces Restructuring
NASDAQ TRADE HALT HALT NEWS PENDING AT 08:25 AM
U.S. STOCKS ON THE MOVE-Ford, Orion Energy, Grocery Outlet
U.S. STOCKS ON THE MOVE-Ford, Splash Beverage, semiconductor stocks, U.S. Bancorp
Yumanity drops on partial clinical hold on U.S. trials of Parkinson's drug
Brief: Yumanity Reports Partial Clinical Hold By U.S. FDA On Multidose Clinical Trials For YTX-7739
Brief: Yumanity Therapeutics Achieved A Milestone Which Triggers A $5 Mln Payment Under Research Collaboration With Merck Sharp & Dohme Corp
Brief: Yumanity Therapeutics Inc Files For Mixed Shelf Of Upto $200 Mln
Yumanity Therapeutics Inc reports results for the quarter ended in September - Earnings Summary
Brief: Yumanity Therapeutics Reports Q3 Loss Per Share $0.97
Yumanity Therapeutics Inc expected to post a loss of $1.13 a share - Earnings Preview
Yumanity slumps as Parkinson's drug trial data disappoints
Brief: Yumanity Therapeutics Announces Positive Top-Line Results Of Phase 1B Clinical Trial For Ytx-7739 In Patients With Parkinson’S Disease Company Plans To Advance Program To Phase 2